Study of Trifarotene Cream to Assess Risk of a Trophic Acne Scar Formation

Key Inclusion Criteria:

• Participant with clinical diagnosis of acne vulgaris on the face as defined by (excluding the nose and middle zone of approximately 2 centimeter [cm]):

1. Investigator's Global Assessment (IGA) score of 3 (Moderate) or 4 (Severe),with the same score on both sides of the face; and

2. A minimum of 20 inflammatory lesions (papules and pustules) in total with atleast 10 on each side; and

3. No more than 2 nodules (greater than or equal to [>=] 1 cm in diameter) on theface; and

4. A minimum of 10 atrophic acne scars in total (>2 mm)

• Participant with a symmetrical number of the following lesions/scars on the wholeface:

1. Inflammatory and non-inflammatory lesions; and

2. Atrophic acne scars (minimum of 4 scars per half-face)

• The participant is a female of non-childbearing potential

• If a female of childbearing, potential uses oral contraceptives that are alsoapprove for treating acne vulgaris

• Other protocol defined inclusion criteria could apply

Key Exclusion Criteria:

• Participant with acne conglobata, acne fulminans, secondary acne, nodulocystic acneand acne requiring systemic treatment

• Participant with any acne cyst on the face or with more than 3 excoriated acnelesions

• Participant with known active or chronic allergies or suspected allergy totrifarotene or excipients of the formulation

• Participant with facial dermal conditions (for example, tattoo, skin abrasion,eczema, sunburned skin, scars, nevi, etc.) that may interfere with study assessmentsin the opinion of the investigator

• Participant with known impaired hepatic or renal functions, based on medical history